Obesity has become a major health problem worldwide. To date, more than 25 different syndromic forms of obesity are known in which one (monogenic) or multiple (polygenic) genes are involved. This review gives an overview of these forms and focuses more in detail on 6 syndromes: Prader Willi Syndrome and Prader Willi like phenotype, Bardet Biedl Syndrome, Alström Syndrome, Wilms tumor, Aniridia, Genitourinary malformations and mental Retardation syndrome and 16p11.2 (micro)deletions. Years of research provided plenty of information on the molecular genetics of these disorders and the obesity phenotype leading to a more individualized treatment of the symptoms, however, many questions still remain unanswered. As these obesity syndromes have different signs and symptoms in common, it makes it difficult to accurately diagnose patients which may result in inappropriate treatment of the disease. Therefore, the big challenge for clinicians and scientists is to more clearly differentiate all syndromic forms of obesity to provide conclusive genetic explanations and eventually deliver accurate genetic counseling and treatment. In addition, further delineation of the (functions of the) underlying genes with the use of array-or next-generation sequencing-based technology will be helpful to unravel the mechanisms of energy metabolism in the general population. plays an important role in this signaling pathway, are the most common causes of monogenic forms of obesity and cumulates to approximately 2% to 5%. 7 However, even for monogenic obesity it has been clear there is an effect of the obesogenic environment on the penetrance. 8 Yet, this manuscript concentrates on a third, rare form of obesity in which genetics play a dominant role: syndromic obesity.
| INTRODUCTION
Obesity is a metabolic disorder characterized by an imbalance between energy intake and expenditure resulting in an excess of adipose tissue. In 1973 Coleman and Hummel showed for the first time that, to a certain extent, genetic factors are responsible for the familial aggregation of obesity. 1 Several years later twin and adoption studies confirmed this and estimated the heritability of body mass index (BMI) at 40% to 70%. [2] [3] [4] There are several types of obesity. The most common is a polygenic type of obesity, which is caused by a combination of genetic and environmental factors such as high-fat diet and sedentary lifestyle, with alarming prevalence and serious complications. This type of obesity is called common or complex obesity. To date, genome-wide association studies (GWAS) identified 97 loci related to complex obesity that account for approximately 2.7% of BMI variation. 5 On the other hand, an even more severe and rare form of obesity is monogenic (non-syndromic) obesity; individuals carry mutations in a single gene that cause the obesity phenotype. Most of the genes affected in monogenic obesity are part of the leptinmelanocortin signaling pathway in the hypothalamus which has an important function in maintaining energy homeostasis. 6 In the European population heterozygous mutations in the melanocortin-4 receptor (MC4R) gene, coding for a G protein-coupled receptor that plays an important role in this signaling pathway, are the most common causes of monogenic forms of obesity and cumulates to approximately 2% to 5%. 7 However, even for monogenic obesity it has been clear there is an effect of the obesogenic environment on the penetrance. 8 Yet, this manuscript concentrates on a third, rare form of obesity in which genetics play a dominant role: syndromic obesity.
| Syndromic obesity
Syndromic obesity refers to obesity occurring in the context of a distinct set of associated clinical phenotypes such as intellectual disability (ID), dysmorphic features and organ-specific developmental abnormalities. 9, 10 Up to now over 25 syndromic forms of obesity have been identified. 11 As shown in Table 1 , syndromic obesity is extremely heterogeneous 144 and different molecular mechanisms underlie the various syndromes. In case of "pleiotropy" one single gene is responsible for the presence of 2 or more distinct and seemingly unrelated traits in the patient. 145 Second, a contiguous gene syndrome (CGS) is a clinical phenotype caused by the absence of a contiguous set of genes with each of the genes underlying one of the unrelated clinical features. The segmental aneuploidy syndrome is a special type of CGS usually originated from non-allelic homologous recombination between low copy repeats that flank the region. A good example of this is the Prader Willi syndrome (PWS). 146 In Table 1 the most important aspects of all syndromic forms of obesity are described. In addition, 6 syndromes were selected for a more detailed discussion. The selection was made in order to illustrate frequent causes, phenotypic overlap, both monogenic causes as well as contiguous gene effects and different types of molecular mechanisms underlying obesity. PWS and Bardet-Biedl syndrome (BBS)
were selected because they are the most prevalent (non-X-linked) obesity syndromes. The Prader Willi like (PWL) phenotype and 16p11.2 (micro)deletions were included due to their clinical similarity with PWS, therefore being important differential diagnostic considerations. Additionally, we also choose Alström syndrome (AS) due to its phenotypic overlap with BBS. Finally, Wilms tumor, Aniridia, Genitourinary malformations and mental Retardation (WAGR) syndrome was selected as it is an excellent example of a CGS (Table 2) .
| PRADER WILLI SYNDROME
PWS is the most common form of syndromic obesity with a prevalence of 1 in 10 000-30 000 live births. It is mainly characterized by severe neonatal hypotonia, feeding difficulties followed by hyperphagia and excessive weight gain, hypogonadism and ID with an average IQ of 65. Characteristic facial features are almond-shaped eyes, a thin upper lip, downturned corners of the mouth and/or a narrow face.
Also behavioral problems (eg, temper tantrums, stubbornness and skin picking), sleep abnormalities, small hands and feet and short stature are frequently described features. 12, 13, [147] [148] [149] In order to clinically diagnose PWS, Holm et al developed a scoring system based on the abovementioned features. Characteristics were divided into 3 groups: major criteria (1 point), minor criteria (0.5 point) and supportive criteria (no points). When younger than 3 years of age, 5 points (at least 4 of them major) are required to diagnose PWS. Eight points (at least 5 of them major) are needed when 3 years or older. 14 Gunay-Aygun et al 148 later modified these clinical criteria to help identify appropriate patients for further diagnostic testing of PWS and which criteria are characteristic at different ages.
In spite of the accuracy of this clinical scoring system, a DNA methylation analysis is always performed to confirm the PWS did not affect weight, appetite or compulsive behavior toward food in the PWS subjects. 44 Another still investigational therapy is the administration of intranasal oxytocin (OXT) to treat hyperphagia. Despite contradictory results of different clinical trials so far, a promising effect on food-related behavior was seen in children with PWS younger than 11 years of age. [45] [46] [47] This hormone shows a high expression in the hypothalamus and, as seen in functional magnetic resonance imaging scans, this brain region also shows a significant delay in activation in PWS patients 48 so further research of the effects of intranasal OXT administration on the hypothalamic activity is still necessary.
In addition, different studies in whole-room indirect calorimeters also indicated a significant reduction in total, resting, sleep and activity energy expenditure in PWS patients compared to age-, sex-and BMImatched subjects. This decrease can be attributed to reduced activity but also to lower energy utilization due to reduced lean body mass which primarily consists of muscle. 49, 50 These results highlight the importance of daily physical activity in PWS patients.
Important to mention, restrictive bariatric surgery is not recommended in PWS as it is associated with high complication rates and even mortality. 51, 52 Also in a case report Fonkalsrud and Bray describe the limited success of a truncal vagotomy to treat obesity in PWS patients as the subject initially lost 29 kg but regained most of this in almost a year time due to almost continuous ingestion of small quantities of food. 53 Other therapies that may benefit PWS patients are the use of serotonin reuptake inhibitors to manage behavioral disorders, especially obsessive-compulsive symptoms and a hormonal replacement therapy in order to produce adequate secondary sexual characteristics at puberty. The latter, however, is somewhat controversial due to the effects of, that is, testosterone replacement on behavior. 38, 54, 147 Noteworthy, recently Kim et al reported a first epigenetics-based therapy for PWS. In a PWS mice model, they restored the expression from the maternal copies of PWS-associated genes by targeting the histone methyltransferase G9a with the use of 2 small molecules UNC0638 and UNC0642. Administration of UNC0642 resulted in the improvement of survival and growth of the pups. However, the effect of the drug on other disease symptoms such as hyperphagia and obesity still needs to be evaluated. 55 As an additional remark, because the genes and pathways disrupted in PWS are also highly conserved in zebrafish, in the future zebrafish could also serve as a promising model for high-throughput screening in order to quickly identify and deliver potential curative pharmacotherapies for PWS patients. 56 As for PWS, PWL therapy is mainly focused on the treatment of the symptoms. As these symptoms are largely comparable, the corresponding treatment of both phenotypes is similar. In addition, depending on the patient's phenotype, specific treatment of epilepsy or cardiovascular abnormalities can be indicated. In case of hearing loss a cochlear hearing device implantation could be a solution.
| Prader Willi like

| BARDET-BIEDL SYNDROME
BBS is a pleiotropic recessive disorder belonging to the family of ciliopathies with a prevalence of 1 in 13 500 (Israel and Arab counties) to 1 in 160 000 (Switzerland) individuals. The big difference in prevalence can be attributed to a high rate of consanguinity in the first population group. [91] [92] [93] )
. Early studies suggested a classical mode of autosomal recessive inheritance for BBS in which a biallelic mutation in one of the affected genes gives rise to the disorder. However, as the years proceeded, the genetics of BBS became more complex.
Katsanis et al was the first to propose a "triallelic inheritance" to manifest the phenotype. They identified a homozygous BBS6 mutation in combination with a heterozygous BBS2 mutation in 1 BBS family and 2 heterozygous BBS2 nonsense mutations and a BBS6 nonsense mutation in BBS patients in 3 other families. 104 This triallelic model was supported by some research groups, 105-108 as others do not underpin the triallelic inheritance hypothesis. [109] [110] [111] [112] [113] [114] In addition, cases are reported in which even healthy individuals carry a biallelic mutation in one of the known BBS genes which suggests incomplete penetrance for at least some genes and/or types of mutations. 96, 104, 107, 115 The only way to achieve molecular confirmation of BBS is the use of clinically available tests. In the past, the most frequently reported mutations, such as p.M390R in BBS1 and p.C91Lfs*5 in BBS10, were identified with the use of simple screening methods such as restriction enzyme digests and/or amplification-refractory mutation system (ARMS) assays. 116 Nowadays targeted high-throughput sequencing, such as next-generation sequencing (NGS) panels, offer the most feasible and effective approach to provide high diagnostic yields as previously used mutation screening techniques are too time-consuming and expensive due to the broad genetic locus heterogeneity of the BBS therapy mainly exists of the treatment of the patient's symptoms. Polydactyly can be surgically corrected. In most children this happens within the first 2 years of age. Second, the management of obesity is initiated at an early age with the use of a low calorie and/or protein diet, exercise and behavioral therapies. 91 One study also discovered a positive effect of the diet on renal function; however, it only may slow the progression of renal failure. 122 Due to the high incidence of renal malformations and abnormal renal function that can lead to end-stage renal disease (ESRD), renal function must be monitored closely. In case of ESRD a renal dialysis and/or renal transplantation are warranted. 91 Third, up till now researchers are unable to prevent the development of blindness in BBS patients. With the use of low vision aids and mobility training they are being prepared to progressive visual loss and possibly blindness by a specialist. However, an experimental set-up of subretinal injection of BBS-containing adenovirus constructs in mice showed encouraging results so far. 91, 96 In case of abnormal gonadotropin or sex hormone levels at puberty, a hormonal replacement therapy in order to produce adequate secondary sexual characteristics can be used in BBS patients. 91 4 | ALSTRÖM SYNDROME
AS was first described in 1959 123 and is, as BBS, included in the ciliopathies group. 124 It is a rare autosomal recessive disorder with a prevalence estimated at 1 to 9 cases per 1 000 000 individuals. To date, approximately 950 cases are described worldwide. before the age of 2 years, whereas in BBS this appears on average 6.5 years later. Polydactyly, which is common in BBS, has not been described in AS. 126 However, since both ciliopathies show considerable phenotypic overlap, especially in early infancy, molecular techniques are crucial to clearly differentiate AS from BBS. 118, 128, 129 AS is caused by homozygous or compound heterozygous mutations in Alström syndrome protein 1 (ALMS1) on chromosome 2p13. tein. 124, 132 In addition, also splice-site mutations, 133 deletions, 134, 135 one Alu transposon insertion 136 and one balanced translocation 137 have been identified in ALMS1.
As ALMS1 localizes to centrosomes and basal bodies of ciliated cells, a role in microtubule organization, intracilia transport, endosome recycling and cell cycle regulations is suggested. 126, 131, 138, 139 Second, it is also hypothesized that ALMS1 could play a role in β-cell function and/or peripheral insulin signaling pathways because AS patients are more likely to develop T2DM in contrast to BBS patients despite the fact that obesity levels are equivalent in both syndromes.
140,141
Unfortunately, up till now the precise molecular mechanism causing the AS phenotype has not been fully elucidated. 132 In the past, the first step in the molecular diagnosis of AS in patients was to perform mutation analysis of the gene hotspots (exons 8, 10 and 16) in ALMS1. When this approach did not reveal any mutation, an array-based technology, which includes a set of known mutations in ALMS1, was often carried out. 124, 128 Nevertheless, as the NGS methodology is rapidly growing and gradually replacing abovementioned technologies, whole-exome and whole-genome sequencing are nowadays the most widely used approaches to identify the causal mutation and secondly also exclude mutations in other genes in the differential diagnosis. 124, 142, 143 As for PWS and BBS, the only therapy for AS patients is restricted to the management of the clinical symptoms and the improvement of the quality of life. 124 Between birth and age 15 months most patients become very sensitive to light (photodysphoria) which can be reduced with the use of red-orange tinted lenses. However, almost all patients have decreasing visual accuracy with loss of light perception around the age of 20 years, although the progression rate is variable. Second, weight gain can be controlled with the use of a healthy, reduced calorie diet and regular exercise taking into account the vision limitations of the patient. 126 Also beneficial effects of rhGH on body composition and liver fat content were reported in a 15-year-old AS patient. ID. Obesity or severe hyperphagia has also been described in a subgroup of these patients, in which case the condition is often called WAGRO. [156] [157] [158] [159] [160] [161] [162] Secondary features often seen in WAGR patients are renal problems, cardiopulmonary defects and behavioral difficulties like autism. 160, 163 Due to the specific combination of manifestations, the differential diagnosis of WAGR is very limited.
WAGR is caused by a de novo heterozygous deletion on chromosome 11p13 in which haploinsufficiency of Wilms tumor 1 (WT1) and paired box 6 (PAX6) is responsible for the core features of the disorder. 155 Evidence is shown that a deletion of WT1 is associated with an increased risk of Wilms tumor, genitourinary anomalies and nephropathies, whereas PAX6 deletions give rise to eye abnormalities. 160, 164 There is also a possibility that PAX6 deficiency results in brain and pancreas defects. [165] [166] [167] [168] Both genes are also located at approximately 4 Mb from the brain-derived neurotrophic factor (BDNF) gene at chromosome 11p14.1. 155, 162 More than half the WAGR patients exhibit a deletion also including this gene who notably all
show childhood obesity compared to only 20% of the patients without a BDNF encompassing deletion 162 ( Figure 3) . Consequently, it is suggested that BDNF is a key player in the obesity phenotype seen in WAGR patients and even in overall energy homeostasis in humans.
BDNF encodes a member of the nerve growth factor family which is involved in neuronal proliferation, differentiation and survival of specific neuronal populations. 6, 169, 170 Its role in energy homeostasis has extensively been investigated resulting in the development of different Bdnf animal models exhibiting an obese phenotype and marked hyperphagia. [171] [172] [173] [174] In addition, as its neural function, the protein is widely distributed in the central nervous system including the hypothalamus. 6, 155 It is believed that BDNF functions within the ventromedial hypothalamic leptin-melanocortin signaling pathway as a downstream target of MC4R and, as a result, is an important effector in the control of energy balance. 175, 176 On the other hand, a recent study determined more severe neurocognitive impairments in WAGR syndrome patients with BDNF haploinsufficiency which shows that BDNF could also be involved in cognitive functioning. 177 Genetic testing for WAGR syndrome is typically performed in children presented with aniridia. 160 To identify large deletions or translocations of chromosome 11p13, high-resolution cytogenetics is an appropriate method. 154, 178 Small deletions, however, cannot be recognized with this technique. In this case, FISH, MLPA or array comparative genomic hybridization (CGH) are more suitable. 160, 162, 164, 178 Once genetic tests confirm the diagnosis of WAGR syndrome, ultrasound screening for Wilms tumor is initiated every 3 months until the age of 5 to 6 years to allow early detection. 160, 178, 179 The prevalence of Wilms tumor in WAGR patients is estimated between 45% 180 and 57%. 160 Depending on the stage of the tumor, patients may require chemotherapy, radiotherapy or even nephrectomy (surgical removal of the kidney). Other renal problems are also frequently reported in which proteinuria or mild hypertension can be an early indication of renal insufficiency and subsequently can be treated with ACE inhibitors. 160, 178 Aniridia should be monitored by an expert ophthalmologist. 178, 181 Colored, tinted contact lenses can be worn to reduce light sensitivity and restore a more normal appearance of the eye, however, due to poor ocular surface and reduced tear production, difficulties can be experienced. 181 That is why implantation of an artificial iris-intraocular lens is nowadays suggested. 181, 182 In case of gonadal dysgenesis, prophylactic removal of the gonads is warranted to prevent the occurrence of gonadoblastoma. 178 
| 16P11.2 (MICRO)DELETIONS
Due to the presence of flanking homologous segmental duplications, the 16p region is particularly prone to rearrangements leading to copy number changes. 183 The recurrent proximal~593 kb deletions (and duplications) are among the most frequent genetic etiologies of autism spectrum disorders (ASD), [184] [185] [186] schizophrenia 187 and neuropsychiatric disorders. 188 The prevalence is estimated at approximately 1% in all ASD cases. 184 In addition, the microdeletion syndrome also cosegregates with severe early-onset obesity, 189, 190 DD, 191 ID, 192, 193 hypotonia, 194 epilepsy, 191, [193] [194] [195] behavioral problems 191, 196 and even a high prevalence of speech articulation abnormalities. 194, 196 On the contrary, patients harboring a~593 kb microduplication share some characteristics with the deletion phenotype, however, confer an increased risk for being underweight indicating that haploinsufficiency and triplosensitivity at the 16p11.2 locus clearly has opposite effects on BMI. To date, no particular candidate gene located within the 593 kb region is pointed forward to clarify the obesity/underweight phenotype. 197 In addition, larger deletions of 1.7 Mb encompassing the 593 kb proximal deletion are also reported in patients harboring similar characteristics 189, 190, 198, 199 supplemented with or without secondary features such as dysmorphism, heart defects 199 or Hirschsprung disease. 200 Noteworthy, this 1.7 Mb deletion also includes a In case of obesity in association with DD or ID, PWS or PWL should be considered as a differential diagnosis. However, as nowadays genome-wide microarray analysis is a routine diagnostic screening method, 16p11.2 (micro)deletions are unlikely to be missed.
Therefore extensive differential diagnosis is useless.
All 4 CNVs (593 kb deletion, 593 kb duplication, 1.7 Mb deletion and 220 kb deletion) are inherited in an autosomal dominant matter, either due to a de novo event or inherited from one of the (even healthy) parents. 183, 189, 198, 204 For the distal 16p11.2 deletion (and the overlapping 1.7 Mb deletion) there is increasing evidence that haploinsufficiency of the Sarcoma (Src) homology 2B adaptor protein 1 (SH2B1) gene could induce the obesity phenotype seen in the patients 197 as other genes within the 220 kb region might clarify the presence of the additional features. 205 Previous research in a yeast 2-hybrid system showed that SH2B1 is a Janus kinase 2 (JAK2)-binding protein. 206 Later on, the same research group showed that, in response to the binding of leptin to its receptor, SH2B1 not only binds to JAK2 but also promotes its activation 207, 208 indicating that SH2B1 could act as a positive regulator of leptin signaling and consequently might be implicated in energy homeostasis. 205 This hypothesis was substantiated further with the generation of a SH2B1 deficient mouse model in which a significant decrease in leptin signaling in the hypothalamus was indicated. The severe obese subjects whereas no private variants were identified in lean control populations. [213] [214] [215] Own research, on the other hand,
showed an equal presence of rare non-synonymous SH2B1 variations in both lean and obese individuals 205 which was also seen in a Chinese study population. 216 Both concluded that it seems unlikely that SH2B1 variants do confer risks for obesity; however, further research is necessary to clarify the contradictory findings. Therapeutically, as for the foregoing disorders, treatment should target the specific features identified. Before excessive weight gain begins, controlling food intake and physical activity at an early age is essential in order to avoid the development of obesity. A neurologist is seen when epilepsy is suspected who will prescribe epileptic medication based on the patient's age, seizure type, electroencephalography (EEG) and side effect profiles. 204 For the management of autism spectrum disorders, different educational interventions such as behavioral strategies and habilitative therapies are used. In addition, to improve communication skills and speech deficits in patients with 16p11.2 microdeletions, different didactic methodologies and developmental-pragmatic approaches are effective. A visit to a speech-language therapist is usually an appropriate first step. 218 
| CONCLUSIONS AND FUTURE PERSPECTIVES
Due to its increasing prevalence and the associated comorbidities, obesity has become a major health problem worldwide. As shown in this review, several genes/chromosomal regions are associated with energy homeostasis. Many years of research already resulted in more information on the molecular genetics of these disorders and the obesity phenotype, however, as discussed in detail for the 6 selected syndromes, treatment of all syndromic forms is only restricted to the Lastly, further delineation of (the functions of ) the underlying genes will be helpful to unravel the mechanisms of energy metabolism in the general population as well. 92 Previous research mostly focused on simple screening methods like Sanger sequencing and FISH; however, due to the extremely heterogeneous character of the different syndromic obesity forms, these techniques are becoming too expensive and time-consuming to screen for disease-causing mutations. Yet nowadays, with the advent of automated DNA sequencing instruments, the NGS technology provides a new method for molecular diagnosis allowing the sequencing of gene panels, whole exomes and even whole genomes. 144, 221 Furthermore, also chromosomal microarrays are routinely utilized in most clinical genetics centers and are already replacing the previously used FISH analysis. 16, 17 To conclude, syndromic obesity is likely to be a monogenic or contiguous gene disorder. Due to its great heterogeneity, nowadays molecular diagnostics is increasingly important in order to make a fast and accurate diagnosis, because an appropriate diagnosis based solely on clinical signs is difficult. Chromosomal microarrays and NGS technology are being introduced as important diagnostic methods. In the near future, it will even be possible to use whole-genome sequencing in order to detect both genomic mutations as well as translocations. However, understanding the clinical phenotypes still remains crucial for accurate counseling of families coping with syndromic obesity and appropriate follow-up of patients.
